Header Ads

Calling all swabs

Here's the latest news from the global pandemic.

All swabs on deck

The Covid-19 pandemic brought the business opportunity of a lifetime to a  family-owned company called Puritan Medical Products. Based in the tiny town of Guilford, Maine, Puritan is the sole Covid swab manufacturer in the U.S. 

Medical swabs are deceptively complex to make, demanding precise manufacturing in proprietary machines to meet hospitals' strict regulatory requirements. The only other company that makes the medical swabs needed for Covid tests, Copan Diagnostics, is based in Italy. 

When the White House realized swabs were the weak link in America's testing supply chain last March, officials called Puritan and asked it to ramp up production 10-fold. But there was a problem: The two cousins who own the company, Timothy Templet and John Cartwright, have long hated each other. Their rift had resulted in delayed investments to modernize manufacturing lines, stagnant wages for a dwindling workforce and an outdated back-office information technology system.

Three weeks before that call, Templet had filed a lawsuit to dissolve the business, citing "major, long-standing and irreconcilable disagreements" with Cartwright.

Covid testing in South Carolina.

Photographer: Micah Green/Bloomberg

The situation was "close to a point where something is going to break," the lawsuit read. "Cartwright and Templet no longer speak, no longer make joint decisions, and are essentially unable even to be in the same room together."

Admiral Brett Giroir, the former testing czar under President Trump, called Templet and Cartwright and asked them to set aside their animosities for the good of the country.

"I remember telling them how critical they were," Giroir recalled. "I said they may not realize it now, but a lot of the pandemic response will depend on them."

The cousins vowed to honor their patriotic duty. Invoking the Defense Production Act, the U.S. invested a quarter of a billion dollars in Puritan to boost its production capacity.

The company now has two new facilities operating in Pittsfield, Maine, and plans for a third in Tennessee. It has doubled headcount, upgraded machines and is set to dominate a global medical swab industry that could be worth as much as $4 billion by 2027.

None of that has quelled the cousins' feud, however. Their fight has continued in private courtroom sessions over the past year, according to previously sealed legal documents obtained by Bloomberg. And those close to the owners say the dispute is likely to become even more fraught, now that Puritan is worth so much more.—Olivia Carville

Ask us anything

We want to know what you need to know. So ask us. Each week we will select one or two commonly asked questions and put them to our network of experts so you and your families can stay safe—and informed. Get in touch here or via CovidQs@bloomberg.net.

Save the Date | Bloomberg New Economy Conversations with Andrew Browne: Big Pharma joined with governments to deliver vaccines in record time. The successful moonshot could spur future research into other affordable drugs. Join us March 23 at 10 a.m. EDT when Katalin Karikó, senior vice president of vaccine pioneer BioNTech, and others discuss Vaccine Miracles and the New Promise of Science. Register here.

What you should read

Are mRNA Vaccines Risky? What the Experts Say
As the technology is so new, the shots are exposed to disinformation drives.
Here's Where Children Lost the Most School Days
Kids in U.S., Mexico and India among those who've been shut out longest.
The U.K. Is Developing Fast Test for Covid Strains
The "genotype assay test" would halve the time it takes to identify variants.
Astra Shot 79% Effective in U.S.; No Safety Issues
It fared better than expected in a U.S. clinical trial, providing reassurance.
EU Vaccine Czar Signals No Need for Sputnik 
Doses "are coming" and the EU doesn't need Russia's Sputnik V vaccine. 

Know someone else who would like this newsletter? Have them sign up here.

Have any questions, concerns, or news tips on Covid-19 news? Get in touch or help us cover the story.

Like this newsletter? Subscribe for unlimited access to trusted, data-based journalism in 120 countries around the world and gain expert analysis from exclusive daily newsletters, The Bloomberg Open and The Bloomberg Close.

No comments